Blockchain Registration Transaction Record

Kairos Pharma to Present New Data on KROS 101 at ASCO Annual Meeting

Kairos Pharma announces presentation of new data on KROS 101, a small molecule GITR ligand agonist, at ASCO Annual Meeting. CEO John Yu highlights the potential of KROS 101 in optimizing cancer treatment. ENV105, Kairos Pharma's lead candidate, targets CD105 to reverse drug resistance in cancer therapies.

This news matters as it highlights the potential of KROS 101 in optimizing cancer treatment, offering hope for overcoming drug resistance and immune suppression in cancer. The presentation at ASCO provides a platform for Kairos Pharma to showcase its innovative approach to addressing unmet medical needs in various cancer types, potentially leading to significant advancements in cancer therapeutics.